Dabigatran etexilate, which is also referred to as Pradaxa, was the first oral direct thrombin inhibitor to receive approval from the Food and Drug Administration (FDA) in the year 2010. Patients who have non-valvular atrial fibrillation are the target population for this medication, which is designed to lower the risk of stroke and systemic embolism from occurring. The data from clinical...